Plasma estrogen concentrations after oral and vaginal estrogen administration in women with atrophic vaginitis.

Abstract

In this open-label, randomized, multiple-dose, two-treatment crossover study, 24 postmenopausal women with moderate to severe atrophic vaginitis received 0.3 mg conjugated estrogens daily for 14 days: 7 days orally (0.3 mg tablet) and 7 days vaginally (0.5 g cream). Steady-state plasma concentrations of E2 and estrone were one-third lower after vaginal versus oral administration of conjugated estrogens.

• Authors: Mary Beth Dorr, Anita L Nelson, Philip R Mayer, Radhika P Ranganath, Paul M Norris, Eileen C Helzner, Richard A Preston
• Journal: Fertility and sterility (Fertil Steril) Vol. 94 Issue 6 Pg. 2365-8 (Nov 2010) ISSN: 1556-5653 [Electronic] United States
• PMID: 20466363 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Chemical References

• Estrogens, Conjugated (USP)
• Vaginal Creams, Foams, and Jellies
• Estrone
• Estradiol

Topics

• Administration, Intravaginal
• Administration, Oral
• Aged
• Atrophy (blood, drug therapy, metabolism)
• Cross-Over Studies
• Drug Administration Schedule
• Estradiol (blood)
• Estrogens, Conjugated (USP) (administration & dosage, blood, pharmacokinetics)
• Estrone (blood)
• Female
• Humans
• Middle Aged
• Osmolar Concentration
• Vagina (drug effects, pathology)
• Vaginal Creams, Foams, and Jellies
• Vaginitis (blood, drug therapy, metabolism)